Coverage Highlights Backlash Over Massive Price Tag for Unproven Treatment, Cost to Taxpayers and Health System
Earlier this month, after the U.S. Food and Drug Administration (FDA) approved brand name drug maker Biogen’s Alzheimer’s treatment aducanumab, brand name Aduhelm, despite serious questions about the medication’s clinical benefit for patients and zero votes in favor of approval from the agency’s expert advisory panel.
Biogen subsequently set a massive launch price of $56,000 on the drug for an annual course of treatment.
Prior to Aduhelm’s approval, the Institute for Clinical and Economic Review (ICER) concluded a fair annual price for the drug, barring major new evidence to support the drug’s efficacy, would fall between $2,500 and $8,300. ICER estimates that at the drug’s current price, Biogen will stand to make more than $50 billion in annual profit from the drug.
The controversial FDA approval and resulting Big Pharma pricing of this unproven treatment have sparked broad-based backlash and increased the momentum in Washington to hold brand name drug companies accountable.
Here are some of the recent headlines generated by the Aduhelm firestorm:
Big Pharma’s Egregious Pricing
Burden on Taxpayers, Health Care System
FDA Approval Controversy
Read more on what patient advocates, physicians and researchers, clinical experts, drug pricing advocates and even Wall Street analysts have had to say on the aducanumab controversy HERE.
Read CSRxP’s statement on the FDA’s decision to approve Aducanumab, and Biogen’s subsequent pricing decision HERE.
Learn more about market-based solutions to hold Big Pharma accountable and lower prescription drug prices HERE.